Lange explained on a conference call that one reason for the miss was a flexible treatment protocol that allowed patients to ...

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

The data from the early-stage obesity study of amycretin is a short-term win for Novo Nordisk amid other factors that weigh ...

In the last reported quarter, the company delivered a negative earnings surprise of 22.37%, as seen in the chart below ... and weight loss medicine, Zepbound. However, in mid-January, Lilly ...

The long answer along with a dosage chart you can find below ... Tirzepatide, sold as Mounjaro and Zepbound, is another GLP-1 agonist and a GIP agonist, too. Its two main effects make it more ...

Eli Lilly and Company LLY will report its fourth-quarter and full-year 2024 earnings on Feb. 6, before market open. The Zacks ...

In the chart above, you can see financial results ... which is the technical name for both Mounjaro and Zepbound, to see if higher doses than what has currently been approved could be made available.

Viking Therapeutics, Inc. offers promising advances in obesity and liver diseases, despite a recent stock drop over GLP-1 market concerns. Click for my VKTX update.